Core Insights - Spruce Biosciences Inc. (NASDAQ:SPRB) experienced a significant stock price increase, rising 34.20% to $175.00 in after-hours trading, following a remarkable 1,378.46% gain during regular trading hours, closing at $130.40 [1][3] Group 1: FDA Designation - On October 6, the FDA granted Breakthrough Therapy Designation to Spruce Biosciences' enzyme replacement therapy, tralesinidase alfa, for treating Sanfilippo Syndrome Type B (MPS IIIB) [2] Group 2: Financial Performance - In Q2, Spruce Biosciences reported a loss of $3.50 per share, which was significantly better than analyst expectations of a $20.25 loss by 82.7%. The company reported no revenue for the quarter, missing the estimated $200,000 [3] - The next earnings report is scheduled for November 10 [3] Group 3: Stock Performance and Market Data - Over the past six months, Spruce Biosciences' stock has surged by 1,996.46%, with a gain of 1,348.89% in the last month alone [3] - The stock has traded between $5.85 and $170.00 over the past year, with a current market capitalization of $73.42 million and an average daily trading volume of 11,170 shares [4] - Benzinga Edge Stock Rankings indicate a negative price trend for SPRB across all time frames [4]